Shield Therapeutics Share Discussion Threads

[zeus19] 13/5/2024 07:37

Cavendish note out his morning. 30p target down from 50p

[qipincha] 10/5/2024 17:50

Finally, they have a mitigation plan,

[weatherman] 10/5/2024 16:04

From the accounts - Going concern: "The Directors have considered scenarios in which sales revenues fall below base case forecasts. In these circumstances mitigating actions such as reduction of discretionary marketing, general and administrative, and production related expenditure combined with the reliance on the full $10.0m accounts receivable facility could be taken to preserve cash. The Directors also believe that other forms of finance, such as royalty finance are likely to be available to the Group."

[gkace] 10/5/2024 15:57

cash more than mcap and no nasty surprises

[qipincha] 10/5/2024 15:33

Now is out phew

[lovewinshatelosses] 09/5/2024 17:09

My only comment is what happened to: 'The Company now expects to issue its fully audited results for FY23 before 10 May 2024'?
Surely not another failure to deliver after statements made to the market in a formal RNS? Lol.

[weatherman] 08/5/2024 20:15

Re: "...amended its existing $20m debt facility agreement with SWK Funding LLC (SWK), with more favourable loan covenant terms."

It is relevant to ask what freedom there is for STX to further renegotiate the loan covenant terms if it looks like being missed again. Evidence of a strongly growing turnover surely reduces the risk for debt finance even if the target numbers are missed in absolute terms. Annualised $16m turnover already from Q1.

Any comments?

[lovewinshatelosses] 06/5/2024 14:03

Really? I got the impression that the CFO did not feel that confident in that premise at all.
Heavily caveated words in relation to the cash-flow positive ambition. Which seems to me to keep being pushed back later and later, while the shares in issue and debt liabilities grow larger and larger.
At least the CEO and CFO put their hand in their pocket this time and bought big.
Oh, wait a minute! No they did not. I must have been asleep and just dreamed of that :)

[ny boy] 03/5/2024 14:08

Highly risky, so anyone buying would expect a big ROI, maybe the recent pump helped some achieve their goals before the dump

Best wait to see if they can recover strongly enough to trade above 35/40p zone. I’ll keep them on my watch list but at current levels extremely high risk imo, so not for me,

Just a gamble not an investment unless they start producing market warming rns’s.

[qipincha] 03/5/2024 11:59

I have watched the recording again yesterday. The difference to previous online meeting is they tried to answer all questions this time. At least all my questions have been covered. The CFO has confirmed the company has sufficient money to turn cashflow positive is 2025 H2. To me, the short term risk eliminated and hope the sale volume will be on track

[reviewwworld] 03/5/2024 11:39

Hopefully not too many of you got puffed into the move earlier in the week. It made no sense given the growth figures all but warranting the selloff into results. If you don't own the stock, don't punt on it. Better to buy at 5p when things have actually turned the corner than bet against the massive odds they will.

[qipincha] 02/5/2024 21:37

positive review:
www.reddit.com/r/Anemic/comments/12aq58b/accruferferric_maltol_working_well_for_me/

[wheeze] 02/5/2024 20:55

The 'lead weight' dragging the price down is confidence that they can meet these targets.I believe the lead weight dragging the price down is a wall of shorting based on their not meeting the loan caveats. This kicked in as soon as they owned up to the duff data. Does anyone really think they would have entered into a loan agreement with such stringent terms without being confident to meet the requirements? Having said that it is a Texas based outfit and one cannot rule out dirty tricks eith the Texas prescribing issue.

[washingmachine] 02/5/2024 20:26

They have quarterly loan caveats
Explained clearly on LSE site
Worth reading/ noting if long
Clearly explained

[weatherman] 02/5/2024 20:21

They have done well to get annualised US sales to around 120,000 or annualised $16m, in the last quarter. Projected sales higher than mkt cap for a fast growing pharma. co.

The latest update has a table of forecast revenues for the loan commitments, which is illuminating - it averages about 30% per quarter, with the most ambitious revenue target between Q3 and Q4, evidently targeting both a higher unit sale price and new sales.
Q2 10% $16.5m / Q3 36% $22.5m / Q4 40% $31.5m / Q1 23% $38.9m / Q2 17% $45.7m

The 'lead weight' dragging the price down is confidence that they can meet these targets.

[purchaseatthetop] 02/5/2024 17:27

Qipincha. All very well but with minimal prescription growth Q1 24 from Q4 23 and with a rather feeble excuse of Texas not having a PBM for Medicaid, if numbers don’t rise fast the cash will continue to burn.

[reviewwworld] 02/5/2024 17:03

"...for a company with a blockbuster drug"Literally what you wrote.Everyone on here knows I'm a long term holder. Lost an absolute fortune. But I've learnt over the years that there those who have sensible comments on this board are let down by the mgmt. Other than that, it's just nonsense about 50 baggers or it's going to 0.

[wheeze] 02/5/2024 16:45

lol reviewworld hold on to your thatch. Never called this a blockbuster but if you think this product is only worth 10 million you are in need of help. My position in STX is clear - I am a holder. Perhaps time to declare your short interest?

[qipincha] 02/5/2024 12:01

the recent downtrend (from Oct 2023) was due to:
1. over-estimated sales target
2. additional funding requirement/risk of dilution.

now issue 2 has been solved without dilution and issue 1 rectified, expect the share price recover

[luckygit] 02/5/2024 11:33

Indeed, looking at the history of Shield over the years, the share price has been in a steady, sometimes collapsing, downward spiral. Sometimes you get into value territory and that's what I see at the present time. Get some decent management in at the top or a takeover then things will change and fast.

[wheeze] 02/5/2024 10:55

In afraid you are mistaken there. Ferinject which is made by Vifor Pharma is an expensive drug and NHS prescribers are encouraged not to use it, nevertheless it has achieved blockbuster status with global sales of 1.15 billion. I am sure you already know this though seek to make disingenuous statements about the value of Acrufer

[bos1234] 02/5/2024 10:53

It is a cheap option versus IV but that doesn't appear to be much on the agenda anymore. The initial trials were misinterpreted but it was still highly effective.